Abstract: Inhalant anesthetics are developed with a number of properties including rapid onset and recovery, controllability, and, ideally, a broad safety profile. The efficacy of these agents is measured by their ability to create anesthesia within the framework of the other desirable properties. The instant invention focuses on the dosage level where analgesia occurs but amnesia or lack of consciousness does not. In addition to identifying the dosage level where pain is sharply reduced or eliminated but awareness remains, a delivery system for safe and effective delivery of the agent is described.

Abstract: Inhalant anesthetics are developed with a number of properties including rapid onset and recovery, controllability, and, ideally, a broad safety profile. The efficacy of these agents is measured by their ability to create anesthesia within the framework of the other desirable properties. The instant invention focuses on the dosage level where analgesia occurs but amnesia or lack of consciousness does not. In addition to identifying the dosage level where pain is sharply reduced or eliminated but awareness remains, a delivery system for safe and effective delivery of the agent is described.

Abstract: A method for the preparation of (CF3)2CHOCH2F (Sevoflurane) is presented, which comprises providing a mixture of (CF3)2CHOCH2Cl, potassium fluoride, water, and a phase transfer catalyst and reacting the mixture to form (CF3)2CHOCH2F.

Abstract: A method for the preparation of (CF3)2CHOCH2F (Sevoflurane) is presented, which comprises providing a mixture of (CF3)2CHOCH2Cl, potassium fluoride, water, and a phase transfer catalyst and reacting the mixture to form (CF3)2CHOCH2F.

Abstract: A method for the preparation of sevoflurane which comprises (a) providing a liquid mixture of (CF3)2CHOCH2Cl, hydrogen fluoride, and an amine and (b) reacting the mixture, to form (CF3)2CHOCH2F.

Abstract: A method for the preparation of sevoflurane which comprises (a) providing a liquid mixture of (CF3)2CHOCH2Cl, hydrogen fluoride, and an amine and (b) reacting the mixture, to form (CF3)2CHOCH2F.

Abstract: Inhalant anesthetics are developed with a number of properties including rapid onset and recovery, controllability, and, ideally, a broad safety profile. The efficacy of these agents is measured by their ability to create anesthesia within the framework of the other desirable properties. The instant invention focuses on the dosage level where analgesia occurs but amnesia or lack of consciousness does not. In addition to identifying the dosage level where pain is sharply reduced or eliminated but awareness remains, a delivery system for safe and effective delivery of the agent is described.

Abstract: A method for the preparation of sevoflurane which comprises (a) providing a liquid mixture of (CF3)2CHOCH2Cl, hydrogen fluoride, and an amine and (b) reacting the mixture, to form (CF3)2CHOCH2F.

Abstract: A method for the preparation of sevoflurane which comprises (a) providing a liquid mixture of (CF3)2CHOCH2Cl, hydrogen fluoride, and an amine and (b) reacting the mixture, to form (CF3)2CHOCH2F.

Abstract: A method for the preparation of sevoflurane which comprises (a) providing a liquid mixture of (CF.sub.3).sub.2 CHOCH.sub.2 Cl, hydrogen fluoride, and an amine and (b) reacting the mixture, to form (CF.sub.3).sub.2 CHOCH.sub.2 F.

Abstract: Disclosed are novel enamine quaternary compounds of the formula ##STR1## wherein m=1, 2 or 3 and n=1, 2 or 3 with the proviso that m+n=3, 4 or 5; R.sup.1 and R.sup.2 are independently lower alkyl or hydrogen, and R.sup.3 and R.sup.4 are independently selected from the group consisting of lower alkyl, lower cycloalkyl lower alkyl, lower alkenyl, phenyl lower alkyl, thienyl lower alkyl, furyl lower alkyl, lower alkoxy lower alkyl, halogenated lower alkyl, lower alkyloyloxo or lower alkyloyloxy lower alkyl or wherein NR.sup.3 R.sup.4 together comprise a heterocycle ring; and wherein X.sup.- represents a pharmaceutically acceptable anion. Pharmaceutical compositions containing the same when administered to warm-blooded animals exhibit a muscle relaxant effect characterized by excellent onset and recovery times. Also disclosed are methods of making the enamine quaternary compounds.

Abstract: The present invention is directed to an anestesia inducing composition comprising a mixture of oxygen gas and an anesthesia inducing effective amount of a compound 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane having the formula ##STR1## The present invention is also directed to methods of inducing and/or maintaining anesthesia by administering the composition in sufficient amounts to warm blooded animals.

Abstract: Compounds are disclosed of the formula ##STR1## optically active isomeric forms thereof, and/or pharmaceutically acceptable acid addition salts thereof, in which formula: R is defined in the disclosure.

Abstract: Processes for the preparation of certain halogenated aliphatic ethers are described, and in particular the preparation of 1,1,2-trifluoro-2-chloroethyl methyl ether, i.e., CH.sub.3 OCF.sub.2 CHFCl. This particular ether has many uses, and is a valuable material for use in the production of the inhalant anesthetic enflurane, 1,1,2-trifluoro-2-chloroethyl difluoromethyl ether, i.e., CF.sub.2 HOCF.sub.2 CHFCl, made and sold under the trademark ETHRANE by Airco, Inc., Montvale, New Jersey 07645.

Abstract: Process for adjusting the halogen content of halogenated aliphatic ethers, by selective replacement of a halide substituent on the ether with a hydrogen. The process is particularly useful for the production of certain inhalant anesthetics.

Abstract: Methods for the dehalogenation of various haloethers are disclosed, comprising providing a haloether having the formula CX'.sub.3 -[CY.sub.2 ].sub.n -O-CZ.sub.2 -CX.sub.3 in which X', Y, Z and X are specifically disclosed combinations of hydrogen, fluorine chlorine and bromine such that the molecule includes at least one reducible group, but where both portions of any ethyl groups present are not reducible. Dehalogenation of these haloethers is carried out by contacting same with a hydrogen donor comprising an amine, preferably a primary or secondary amine or a primary, secondary or tertiary alkanol amine. The amine is preferably used in combination with a catalyst, such as a varivalent metal or a salt thereof, such as copper or a copper salt.

Abstract: This disclosure is directed to novel ethers of the formula:CF.sub.3 CH.sub.a X.sub.b --O--CF.sub.2 CH.sub.c F.sub.d Cl.sub.ewherein X is fluorine, chlorine or bromine, preferably fluorine, a is 1 or 2, b is 0 or 1, a plus b are 2, preferably both a and b being 1, c is 0 or 1, d is 0 to 2, e is 0 to 2, c plus d plus e are 3, preferably each of c, d, and e is 1, and a plus c are 1 or 2, preferably 2, with the proviso that when e is 1 or 2, X is fluorine or bromine, preferably fluorine. The compounds having less than eight fluorine atoms per molecule are useful as anesthetics, and all of the compounds are useful as solvents and dispersants for fluorinated materials. A highly preferred compound useful as an anesthetic is 1,2,2,2-tetrafluoroethyl 1',1',2'-trifluoro-2'-chloroethyl ether.

Abstract: This disclosure is directed to novel ethers of the formula:CF.sub.3 CH.sub.a X.sub.b --O--CF.sub.2 CH.sub.c F.sub.d Cl.sub.ewherein X is fluorine, chlorine or bromine, preferably fluorine, a is 1 or 2, b is 0 or 1, a plus b are 2, preferably both a and b being 1, c is 0 or 1, d is 0 to 2, e is 0 to 2, c plus d plus e are 3, preferably each of c, d, and e is 1, and a plus c are 1 or 2, preferably 2, with the proviso that when e is 1 or 2, X is fluorine or bromine, preferably fluorine. The compounds having less than eight fluorine atoms per molecule are useful as anesthetics, and all of the compounds are useful as solvents and dispersants for fluorinated materials. A highly preferred compound useful as an anesthetic is 1,2,2,2-tetrafluoroethyl 1',1',2'-trifluoro-2'-chloroethyl ether.

Abstract: Cyclic ether compounds of the formula ##STR1## wherein n is zero or one, and each X is F when n is zero and is H when n is one, are useful as inhalation anesthetics.

Abstract: Aliphatic ether compounds of the formula ##EQU1## wherein n is zero or one, and --X is --CF.sub.3 or --H when n is zero and is --OCH.sub.3 when n is one, are useful as inhalation anesthetics.